ATRA
Atara Biotherapeutics Inc
$
14.850
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
14.890
Open
13.990
VWAP
14.55
Vol
51.47K
Mkt Cap
104.29M
Low
13.990
Amount
749.01K
EV/EBITDA(TTM)
4.21
Total Shares
4.90M
EV
117.29M
EV/OCF(TTM)
--
P/S(TTM)
0.81
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
42.75M
-56.45%
2.460
-29.71%
3.24M
-90.12%
-0.605
-49.16%
2.74M
-93.19%
-0.665
-77.3%
Estimates Revision
The market is revising Upward the revenue expectations for Atara Biotherapeutics, Inc. (ATRA) for FY2025, with the revenue forecasts being adjusted by 5.21% over the past three months. During the same period, the stock price has changed by 31.18%.
Revenue Estimates for FY2025
Revise Upward
+5.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+82.01%
In Past 3 Month
Stock Price
Go Up
+31.18%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 16.50 USD with a low forecast of 16.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 14.850
Low
16.00
Averages
16.50
High
17.00
Current: 14.850
Low
16.00
Averages
16.50
High
17.00
Canaccord Genuity
John Newman
Strong Buy
Maintains
$17
2025-03-11
Reason
Canaccord Genuity
John Newman
Price Target
$17
2025-03-11
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
n/a
2025-01-28
Reason
HC Wainwright & Co.
Robert Burns
Price Target
n/a
2025-01-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
n/a
2025-01-22
Reason
HC Wainwright & Co.
Robert Burns
Price Target
n/a
2025-01-22
Reiterates
Hold
Reason
Canaccord Genuity
John Newman
Strong Buy
Maintains
$21 → $17
2025-01-17
Reason
Canaccord Genuity
John Newman
Price Target
$21 → $17
2025-01-17
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Atara Biotherapeutics to $17 from $21 and keeps a Buy rating on the shares. The firm noted Atara received a Complete Response Letter (CRL) for Ebvallo on inspection findings from a third-party manufacturer, which we think can be resolved, with a 6-month review on resubmission. The target was reduced due to delayed Ebvallo approval and the potential to halt CAR-T development 1Q25.
Rodman & Renshaw
Tony Butler
Strong Buy
Initiates
$25
2024-12-20
Reason
Rodman & Renshaw
Tony Butler
Price Target
$25
2024-12-20
Initiates
Strong Buy
Reason
Rodman & Renshaw analyst Tony Buter initiated coverage of Atara Biotherapeutics with a Buy rating and $25 price target. Atara is developing T-cell immunotherapies with a focus on the development of therapies for patients with cancer and autoimmune diseases, the analyst tells investors in a research note. The firm believes Atara is unique for a number of reasons among allogeneic cell therapy developers given its use of intact T-cell receptors, the incorporation of the 1XX chimeric antigen receptors, and the use of T-cells with memory stem cell phenotype.
Canaccord Genuity
John Newman
Strong Buy
Maintains
$13 → $21
2024-11-13
Reason
Canaccord Genuity
John Newman
Price Target
$13 → $21
2024-11-13
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Atara Biotherapeutics Inc (ATRA.O) is 23.95, compared to its 5-year average forward P/E of -0.58. For a more detailed relative valuation and DCF analysis to assess Atara Biotherapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.58
Current PE
23.95
Overvalued PE
5.32
Undervalued PE
-6.48
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.68
Current EV/EBITDA
-31.14
Overvalued EV/EBITDA
3.94
Undervalued EV/EBITDA
-9.31
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
16.07
Current PS
14.85
Overvalued PS
41.61
Undervalued PS
-9.47
Financials
Annual
Quarterly
FY2025Q2
YoY :
-38.63%
17.58M
Total Revenue
FY2025Q2
YoY :
-126.41%
4.72M
Operating Profit
FY2025Q2
YoY :
-112.53%
2.39M
Net Income after Tax
FY2025Q2
YoY :
-104.90%
0.19
EPS - Diluted
FY2025Q2
YoY :
-31.44%
-7.32M
Free Cash Flow
FY2025Q2
YoY :
+15.52%
96.85
Gross Profit Margin - %
FY2025Q2
YoY :
-85.14%
-33.93
FCF Margin - %
FY2025Q2
YoY :
-120.42%
13.58
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 259.72% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
76.3K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
856.8K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 192.53% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
30.9K
Volume
1
0-12
Months
10.6K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
41.0K
Volume
Months
0-12
2
39.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 259.72% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
76.3K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
856.8K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATRA News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
16:02:22
Atara Biotherapeutics reports Q2 EPS 19c vs. ($3.10) last year
2025-07-24 (ET)
2025-07-24
09:01:34
Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA
2025-07-24
08:03:16
Atara Biotherapeutics announces FDA acceptance of BLA for tabelecleucel
Sign Up For More Events
Sign Up For More Events
News
2.0
09-29Benzinga4 Biotechnology Stocks Leading the Way with Strong Momentum and Technical Performance
5.0
09-03NewsfilterAtara Biotherapeutics Reveals Board of Directors Restructuring
9.0
07-24NASDAQ.COMAtara To Face FDA Again In Jan.2026 - Will The Second Time Be The Charm For Tab-cel?
Sign Up For More News
People Also Watch
AERT
Aeries Technology Inc
0.653
USD
-3.40%
TLF
Tandy Leather Factory Inc
3.020
USD
+0.67%
PASG
Passage Bio Inc
7.680
USD
+3.78%
PTLE
PTL Ltd
0.164
USD
-6.83%
HHS
Harte Hanks Inc
3.110
USD
+1.63%
MOVE
Movano Inc
5.700
USD
-14.03%
DSWL
Deswell Industries Inc
3.440
USD
+5.20%
PYPD
PolyPid Ltd
3.830
USD
-0.26%
VRME
VerifyMe Inc
0.986
USD
+1.65%
GRCE
Grace Therapeutics, Inc
3.155
USD
-1.10%
FAQ
What is Atara Biotherapeutics Inc (ATRA) stock price today?
The current price of ATRA is 14.85 USD — it has increased 5.73 % in the last trading day.
What is Atara Biotherapeutics Inc (ATRA)'s business?
What is the price predicton of ATRA Stock?
What is Atara Biotherapeutics Inc (ATRA)'s revenue for the last quarter?
What is Atara Biotherapeutics Inc (ATRA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Atara Biotherapeutics Inc (ATRA)'s fundamentals?
How many employees does Atara Biotherapeutics Inc (ATRA). have?